- Extensive in-house experience in industrial drug discovery and development for small-molecule pharmaceuticals.
- Strong patent application preparation and prosecution experience in technological disciplines ranging from organic chemistry, polymers, advanced materials, oil and gas operations, hydraulic fracturing technology, cosmetics, drug discovery and development, and biological sciences, to semiconductor and LED manufacturing.
- Freedom-to-operate and validity studies in support for strategic legal counseling, negotiations, business transactions, planning, licensing and venture capital investments.
- Strong skills in legal and technical due diligence.
Prior to joining Abel IP, Thomas was a patent practitioner for six years with Greenblum & Bernstein PLLC, in the DC metro area. There, he developed a close working relationship with the USPTO, interviewing Examiners regularly, and practicing with and mentoring under senior attorneys, many of whom were ex-Examiners from the USPTO. Previous to that, Thomas was a scientist in the drug discovery and development department at AstraZeneca R&D in Waltham, Massachusetts.
Area of Practice
- Intellectual Property
- Technology Transactions
- New Materials
- Small-Molecule Pharmaceuticals
- Synthetic Biology
- Oil and Gas
- Hydraulic Fracturing Technology
- Medical Devices
- Semiconductor Manufacturing
- Licensed to practice before the U.S. Patent and Trademark Office
- American Chemical Society
- German Chemical Society (GDCh)
- Ph.D. (Organic and Medicinal Chemistry), University of Houston, TX, 2002
- J.D., The Catholic University of America, Columbus School of Law, Washington, D.C. 2010
- Dipl. Chem., Universität des Saarlandes, Germany, 1997
- Co-inventor of “Oxazolidinone and/or Isooxazoline derivatives as Antibacterial Agents” International Patent Appl. Pub. # WO 2004/048392 A1
- Co-inventor of “Novel Rho Inhibitors” International Patent Appl. Pub. # WO 2004/004464 A1
- First Author of “Metals in Rho-mediated processes: New leads for drug discovery”, Biochemistry 42, (2002), 9121-9126
- First Author of “Metal Dependency for Transcription Factor Rho Activation” Biochemistry 42, (2002), 1652-1659
- First Author of “The Mg2+ Requirements for Rho Transcription Termination Factor: Catalysis and Bicyclomycin Inhibition” Biochemistry 41, (2002), 12377-12383